poisar

Stocks · News reference

Gilead Sciences Announces Expansion Of Six Royalty-Free Voluntary Licensing Agreements To Cover Once-Yearly Lenacapavir For HIV Prevention Across 120 Countries

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GILD
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Robert Izquierdo

    Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH

    The Invesco Nasdaq Biotechnology ETF (IBBQ) offers lower costs (0.19% expense ratio) and higher 1-year returns (44.6%), making it suitable for growth-focused investors willing to accept volatility. The iShares U.S. Healthcare ETF (IYH) provides broader diversification across 100 healthcare holdings with higher dividend yield (1.1%) and lower volatility, appealing to conservative investors seeking stability and income.

    IBBQIYHLLYJNJABBV
  2. Researchandmarkets.Com

    Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities

    A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.

    AMGNPFENVSGILDREGN